Citigroup
CNTX icon

Citigroup’s Context Therapeutics CNTX Stock Holding History

Citigroup’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39K Buy
70,323
+58,141
+477% +$118K ﹤0.01% 5040
2026
Q1 		$31.9K Buy
12,182
+10,834
+804% +$25.3K ﹤0.01% 4681
2025
Q4 		$1.98K Buy
+1,348
New +$1.57K ﹤0.01% 5457
2025
Q1 		– Sell
-54,454
Closed -$57.2K – 5652
2024
Q4 		$57.2K Buy
54,454
+9,675
+22% +$16.7K ﹤0.01% 5053
2024
Q3 		$87.8K Buy
+44,779
New +$99.3K ﹤0.01% 4816

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Citigroup's CNTX Position: Q2 2026 in Review

Citigroup increased its Context Therapeutics (CNTX) stake by 477% in Q2 2026, buying an estimated $118K and bringing the position to 70,323 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #5040.

Citigroup first reported a position in CNTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $87.8K in Q3 2024. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Citigroup held 70,323 shares of Context Therapeutics worth $39K as of Q2 2026.
  • Citigroup bought 58,141 Context Therapeutics shares in Q2 2026, an estimated $118K.
  • Context Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5040 holding.
  • Citigroup first reported a position in Context Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Citigroup's Context Therapeutics position peaked at $87.8K in Q3 2024.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.